What You Should Know:
– Nucleus RadioPharma, the world’s first comprehensive radiopharmaceutical organization, today announced the closing of an extended Series A funding round with the addition of new investor AstraZeneca.
– The strategic investment bolsters Nucleus’ mission to make targeted radiotherapies and theranostics more accessible to patients worldwide.
AstraZeneca Joins Forces with Leading Radiopharmaceutical Innovator
AstraZeneca joins a distinguished group of existing investors, including GE Healthcare, Mayo Clinic, and Eclipse Ventures. This combined financial backing empowers Nucleus to accelerate the development, supply, and commercial manufacturing of radiopharmaceuticals, a promising advancement in oncology.
Dr. Tyrell Rivers Appointed to Board of Directors
Concurrent with the funding announcement, Nucleus named Dr. Tyrell Rivers to its Board of Directors. Dr. Rivers serves as Executive Director of Corporate Ventures at AstraZeneca, where he spearheads the creation and execution of innovative business strategies.
Dr. Rivers brings over two decades of experience in life sciences and investment to the Nucleus Board. His expertise spans company growth strategies, corporate direction, and establishing financially sound businesses. Dr. Rivers currently serves on the boards of ADC Therapeutics, Cellectis, Cerapedics, and Quell Therapeutics.
Theranostics: Personalized Cancer Treatment
Theranostics, a revolutionary approach to cancer treatment, combines diagnostic and therapeutic elements. Radiotracers are used to identify and target specific cancer cells. A low dosage helps visualize tumors, guiding targeted therapy, while a higher dose delivers potent radiation to eliminate cancer cells while minimizing damage to healthy tissue. This precision approach offers reduced side effects compared to traditional treatments and holds promise for treating metastatic cancers.
Revolutionizing Radiopharmaceutical Accessibility
Radiopharmaceuticals offer a precise approach to battling cancer. However, the complex supply chain, often likened to managing a melting ice cube, necessitates precise timing due to the perishable nature of radioactive materials. This complexity limits patient access to these promising treatments. Nucleus RadioPharma stands at the forefront of tackling these challenges by optimizing manufacturing and supply chain efficiencies, ultimately expanding access to radiopharmaceuticals – a new frontier in cancer treatment.
“Theranostic radiopharmaceuticals represent a new hope for millions of people with limited treatment alternatives,” said Nucleus RadioPharma CEO Charles S. Conroy. “These drugs, designed for precise targeting, are demonstrating remarkable effectiveness while upholding an exceptional safety record. The funding expands the accessibility and impact of these life-saving treatments, paving the way for large-scale production and instilling optimism in those with limited options.
